Clinical Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma

临床核心：IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性

• 批准号: 10589805
• 负责人: MICHAEL E PICHICHERO
• 金额: $ 30.47万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-10 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10589805
• 关键词: 3 year old; Adjuvant; Africa; Age; Antibody Response; Asthma; Canada; Child; Child Health; Clinical; Clinical Trials; Communicable Diseases; Data; Development; Disease; Functional disorder; Future; Geography; Goals; Growth; Health; Hypersensitivity; Immune; Immune System Diseases; Immune response; Immune system; Immunologic Memory; Immunologics; Immunology procedure; Impairment; Incidence; Infant; Infection; Infection prevention; Intervention; Intestines; Investigation; Lead; Life; Longitudinal cohort study; Measures; Modernization; Molecular; Mucous Membrane; Nasopharynx; Papua New Guinea; Phenotype; Population; Predisposition; Prospective cohort; Proteins; Proteomics; Respiratory Tract Infections; Sampling; Secure; Shapes; Systems Biology; Testing; Vaccination; Vaccines; Validation; Variant; biobank; biomarker development; biomarker discovery; clinical phenotype; cohort; data exchange; early childhood; immune modulating agents; metabolomics; microbiome research; mortality; multiple omics; predictive marker; prevent; prospective; recruit; respiratory; tool; transcriptomics; vaccine response; vaccine-induced antibodies

Project Summary/Abstract – Clinical Core (CC) The Clinical Core (CC) will provide and coordinate sharing of existing biorepository and new prospective clinical samples collected from the systemic and mucosal (intestinal and nasopharyngeal) compartments from past and ongoing early childhood cohorts to enable characterization of vaccine response-specific, respiratory infection- specific, and asthma-specific OMIC signatures and endotypes. These discoveries will inform interventions that may redirect unfavorable IDEAL endotypes associated with disease to those associated with health. Specifically, the CC will: 1. Coordinate transfer of biorepository clinical samples from the four early life cohorts (EPIC-HIPC, VDAART, Rochester Combined Cohort (RCC), and CHILD) that together will comprise our IDEAL Meta Cohort (IMC) to Cores/Projects for OMIC and immune assays; 2. Measure vaccine induced antibody levels in VDART and CHILD cohorts; and 3. Recruit a well-defined prospective infant cohort to provide new samples for validation testing, confirm predictive biomarkers, test mechanistic hypotheses, identify immunomodulatory agents (e.g., proteins, metabolites, adjuvants or vaccines) overcoming impaired phenotype, and secure a new biorepository for future investigations.

项目总结/摘要-临床核心（CC） 临床核心（CC）将提供并协调现有生物储存库和新的前瞻性临床 从过去的全身和粘膜（肠和鼻咽）隔室收集的样本， 正在进行的儿童早期队列研究，以确定疫苗反应特异性呼吸道感染的特征- 特异性和哮喘特异性OMIC特征和内型。这些发现将为干预措施提供信息， 可能将与疾病相关的不利IDEAL内型重定向到与健康相关的那些。具体地说， 协调委员会将： 1.协调转移来自四个早期生命队列（EPIC-HIPC、VDAART、 罗切斯特联合队列（RCC）和儿童），共同组成我们的理想Meta队列（IMC）， 用于OMIC和免疫测定的核心/项目; 2.测量VDART和CHILD队列中疫苗诱导的抗体水平;以及 3.招募一个定义明确的前瞻性婴儿队列，为验证测试提供新样本，确认 预测性生物标志物，测试机理假设，鉴定免疫调节剂（例如，蛋白质， 代谢物，佐剂或疫苗）克服受损的表型，并为未来提供新的生物储存库 调查事务所